Literature DB >> 22218709

Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.

Shingo Takano1.   

Abstract

Glioblastomas are highly vascular tumors. Recent preclinical and clinical investigations have revealed that agents targeting angiogenesis may have efficacy against this type of tumor. Antibodies to vascular endothelial growth factor are being studied in this patient population. Unfortunately, treatment inevitably fails. This review provides an update on recent research on the mechanisms by which tumor cells acquire resistance, and discusses recent preclinical and experimental development of novel new-generation anti-angiogenic agents that overcome this problem, especially those based on the molecular mechanisms of tumor vessel formation. The tumor vasculature not only nourishes glioblastomas, but also provides a specialized microenvironment for tumor stem-like cells and for the brain tumor. The factors, pathways, and interactions described in this review provide information about the cell biology of glioblastomas which may ultimately result in new modes of treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22218709     DOI: 10.1007/s10014-011-0077-6

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  21 in total

Review 1.  Using the molecular classification of glioblastoma to inform personalized treatment.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

2.  High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.

Authors:  Josep Puig; Gerard Blasco; Josep Daunis-I-Estadella; Angel Alberich-Bayarri; Marco Essig; Rajan Jain; Sebastián Remollo; David Hernández; Montserrat Puigdemont; Javier Sánchez-González; Gloria Mateu; Max Wintermark; Salvador Pedraza
Journal:  Neuroradiology       Date:  2015-10-05       Impact factor: 2.804

3.  Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.

Authors:  Jason H Stafford; Takahisa Hirai; Lei Deng; Sophia B Chernikova; Kimiko Urata; Brian L West; J Martin Brown
Journal:  Neuro Oncol       Date:  2015-11-03       Impact factor: 12.300

Review 4.  Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.

Authors:  Rong Shao; Sherry L Taylor; Dennis S Oh; Lawrence M Schwartz
Journal:  Oncotarget       Date:  2015-12-01

5.  ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.

Authors:  Oliver Bähr; Stefanie Gross; Patrick N Harter; Elmar Kirches; Christian Mawrin; Joachim P Steinbach; Michel Mittelbronn
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

Review 6.  Neurovascular development and links to disease.

Authors:  Christiana Ruhrberg; Victoria L Bautch
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

7.  Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas.

Authors:  Chun-I Sze; Wan-Pei Su; Ming-Fu Chiang; Chen-Yu Lu; Yu-An Chen; Nan-Shan Chang
Journal:  Front Oncol       Date:  2013-03-19       Impact factor: 6.244

8.  Apoptosis in glioma-bearing rats after neural stem cell transplantation.

Authors:  Hua Li; Zhenjun Chen; Shaopeng Zhou
Journal:  Neural Regen Res       Date:  2013-07-05       Impact factor: 5.135

Review 9.  Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial.

Authors:  Shingo Takano; Eiichi Ishikawa; Kei Nakai; Masahide Matsuda; Tomohiko Masumoto; Tetsuya Yamamoto; Akira Matsumura
Journal:  Onco Targets Ther       Date:  2014-09-05       Impact factor: 4.147

10.  Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.

Authors:  Xiao Yu Wu; Hao Xu; Zhen Feng Wu; Che Chen; Jia Yun Liu; Guan Nan Wu; Xue Quan Yao; Fu Kun Liu; Gang Li; Liang Shen
Journal:  Oncotarget       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.